Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STAA 
STAAR Surgical Company (STAA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: STAA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $25.88
1 Year Target Price $25.88
| 3 | Strong Buy |
| 0 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.66% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.30B USD | Price to earnings Ratio - | 1Y Target Price 25.88 |
Price to earnings Ratio - | 1Y Target Price 25.88 | ||
Volume (30-day avg) 14 | Beta 0.83 | 52 Weeks Range 13.50 - 32.00 | Updated Date 10/26/2025 |
52 Weeks Range 13.50 - 32.00 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When After Market | Estimate 0.21 | Actual 0.1614 |
Profitability
Profit Margin -42.45% | Operating Margin (TTM) -55.63% |
Management Effectiveness
Return on Assets (TTM) -10.71% | Return on Equity (TTM) -25.55% |
Valuation
Trailing PE - | Forward PE 62.5 | Enterprise Value 1203927052 | Price to Sales(TTM) 5.78 |
Enterprise Value 1203927052 | Price to Sales(TTM) 5.78 | ||
Enterprise Value to Revenue 5.36 | Enterprise Value to EBITDA 42.84 | Shares Outstanding 49354123 | Shares Floating 27365664 |
Shares Outstanding 49354123 | Shares Floating 27365664 | ||
Percent Insiders 0.61 | Percent Institutions 109.69 |
Upturn AI SWOT
STAAR Surgical Company
Company Overview
History and Background
STAAR Surgical Company was founded in 1982. Initially focused on intraocular lenses (IOLs) for cataract surgery, it later shifted its focus to refractive vision correction with the development of the Visian ICL (Implantable Collamer Lens).
Core Business Areas
- ICL (Implantable Collamer Lens): STAAR's primary business segment revolves around the Visian ICL, a phakic intraocular lens used for correcting myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. It's a refractive procedure that provides an alternative to LASIK.
- Cataract Lenses: STAAR also offers a range of intraocular lenses (IOLs) for cataract surgery, though this segment is secondary to the ICL business.
Leadership and Structure
The leadership team includes Tom Frinzi (President and CEO) and Patrick Furlotti (Chief Financial Officer). The organizational structure is typical of a publicly traded medical device company, with departments such as R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Visian ICL: The Visian ICL is STAAR Surgical's flagship product. It corrects myopia, hyperopia, and astigmatism. Market share is estimated to be around 25% of the refractive lens market, with ongoing growth. Competitors include Johnson & Johnson Vision (JJNJ), Alcon (ALC), and Carl Zeiss Meditec (AFX.DE).
- Cataract IOLs: STAAR offers a range of IOLs for cataract surgery. The market share for this product is significantly smaller than the ICL. Competitors include Johnson & Johnson Vision (JJNJ), Alcon (ALC), and Bausch & Lomb (BHC).
Market Dynamics
Industry Overview
The refractive surgery market is growing, driven by increasing demand for vision correction and technological advancements. The cataract surgery market is also expanding due to an aging global population.
Positioning
STAAR Surgical is positioned as a leading provider of premium refractive vision correction solutions, specifically with the Visian ICL. It differentiates itself through its lens material (Collamer), minimally invasive procedure, and perceived safety and efficacy.
Total Addressable Market (TAM)
The TAM for refractive surgery is estimated to be in the billions of dollars annually. STAAR is positioned to capture a growing share of this market through continued innovation and expansion into new geographic regions.
Upturn SWOT Analysis
Strengths
- Proprietary Collamer material
- Minimally invasive procedure
- Strong brand recognition in the ICL market
- Growing global presence
- High patient satisfaction
Weaknesses
- Reliance on a single primary product (ICL)
- Higher cost compared to LASIK
- Limited presence in the cataract IOL market relative to larger competitors
- Requires specialized surgical training
Opportunities
- Expanding into new geographic markets (e.g., China, India)
- Developing new ICL designs for presbyopia correction
- Increasing awareness of the Visian ICL among surgeons and patients
- Partnering with ophthalmology clinics and hospitals
Threats
- Competition from LASIK and other refractive surgery technologies
- Economic downturns affecting consumer spending on elective procedures
- Regulatory changes impacting medical device approvals
- Adverse events or complications associated with ICL implantation
Competitors and Market Share
Key Competitors
- JNJ
- ALC
- AFX.DE
Competitive Landscape
STAAR's competitive advantage lies in its proprietary Collamer material and minimally invasive ICL procedure. However, it faces competition from larger companies with broader product portfolios, such as Johnson & Johnson Vision and Alcon.
Growth Trajectory and Initiatives
Historical Growth: STAAR has experienced significant revenue growth in recent years, driven by increased ICL sales.
Future Projections: Analyst estimates project continued revenue growth for STAAR, driven by increasing demand for the Visian ICL. Check recent analyst reports.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts in key markets, launching new ICL designs, and investing in clinical research.
Summary
STAAR Surgical shows promise, demonstrating a strong position in the refractive lens market with its Visian ICL. Key strengths are the company's proprietary technology and patient outcomes. Challenges may come in expanding market presence, and competition. STAAR's growth potential hinges on further innovation and expansion into international markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Analyst reports
- Company press releases
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and subject to change. Actual financial performance may differ from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STAAR Surgical Company
Exchange NASDAQ | Headquaters Lake Forest, CA, United States | ||
IPO Launch date 1983-07-15 | CEO & Director Mr. Stephen C. Farrell CFA | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1157 | Website https://www.staar.com |
Full time employees 1157 | Website https://www.staar.com | ||
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.